Compare AGNC Investment Corp (AGNC) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AGNC Investment Corp vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? AGNC Investment Corp trades at $10.96 (market cap $12.76B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $283.32 (market cap $7.85B). The key difference: AGNC Investment Corp is the larger of the two by market cap, and AGNC Investment Corp pays a 12.95% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| AGNC | BIO | |
|---|---|---|
Market Cap | $12.76B | $7.85B |
Sector | Financials | Health |
52-Week High | $12.17 | $339.75 |
52-Week Low | $9.20 | $241.71 |
Dividend Yield | 12.95% | — |
Enterprise Value | — | $7.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC trades at $11.12, up 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $11.33. The stock shows strong profitability with a net income margin of 91.71% and ROE of 13.98%, though recent earnings have been mixed with a Q1 2026 beat but misses in prior quarters. Dividend payments of $0.12 per share continue regularly, supporting income-focused investors amid interest rate sensitivity concerns highlighted in recent news.
Outlook remains cautiously optimistic given analyst buy ratings (37.14%) and technical momentum, but risks include Federal Reserve policy shifts impacting mortgage-backed securities and earnings volatility. The stock's valuation at P/E 8.73 and P/B 1.26 offers relative value, though investors must monitor interest rate trends for dividend sustainability and book value stability.
BIO trades at $292.50, down 1.47% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.58B for 2025 with net income of $759.90M, though it missed EPS estimates for three consecutive quarters. Positive cash flow from operations of $532.20M supports financial health, while recent news highlights Nasdaq compliance and industry participation.
Outlook remains cautiously optimistic with a consensus price target of $305.00, representing ~4% upside. Risks include consistent earnings misses and high P/E of 49.11, but strong analyst buy sentiment (53.85%) and improving profitability margins offer potential for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
